Orexin / wakefulness arousal axis

Category: receptor_pharmacology

Overview

Lateral hypothalamic orexin (hypocretin) neurons project broadly to monoaminergic + cholinergic arousal nuclei (LC, raphe, TMN, BF), stabilizing wakefulness. Orexin loss (autoimmune destruction of LH neurons) is the proximal cause of narcolepsy type 1. Pharmacology: dual orexin receptor antagonists (DORAs — suvorexant, lemborexant, daridorexant) block OX1 + OX2 to induce sleep without GABA-A modulation (lower fall + cognitive risk vs benzos). Modafinil's wake-promoting action is partly via orexin-system activation (DAT-low-affinity inhibitor with downstream orexin amplification). Caffeine's wake effect is via A1/A2A adenosine antagonism — adenosine accumulates during waking + inhibits orexin neurons; caffeine removes that inhibition.

Organ Systems

• nervous

Pathway Steps

1. orexin-release → monoaminergic-arousal — via OX1/OX2 receptors on LC noradrenergic + raphe serotonergic + TMN histaminergic + BF cholinergic neurons → wake-promotion. Hypothalamic orexin (hypocretin) neurons stabilize wakefulness by exciting the monoaminergic and cholinergic arousal systems. Loss of orexin neurons causes narcolepsy with cataplexy — and orexin’s role made it the target of the “orexin-receptor antagonist” hypnotics (suvorexant).
2. adenosine → orexin-release — via A1 receptors on orexin neurons inhibit firing; rising adenosine across waking hours promotes sleep pressure. Accumulating adenosine (the sleep-pressure signal) and circadian inputs modulate orexin-neuron activity, integrating homeostatic and circadian drives. This places orexin at the hub balancing sleep and wake — and explains why caffeine (an adenosine antagonist) promotes arousal partly through this system.

Known Modulators

• suvorexant (inhibitor) — OX1 + OX2 (DORA). first DORA (Belsomra 2014); ~12h half-life can drag into next morning; next-day driving warning
• lemborexant (inhibitor) — OX1 + OX2 (DORA, OX2-biased). Dayvigo 2019; faster sleep-onset profile than suvorexant; SUNRISE trials
• daridorexant (inhibitor) — OX1 + OX2 (DORA). Quviviq 2022; shortest half-life of the DORAs (~8h) — minimizes next-day residual sedation
• modafinil (activator) — orexin neurons (indirect via DAT + downstream activation). wake-promoting; narcolepsy + shift-work + OSA-residual sleepiness indications; CYP3A4 inducer (multi-DDI perpetrator Wave 2a v1.1)
• armodafinil (activator) — orexin neurons (indirect). R-enantiomer of modafinil; longer t½ allows once-daily morning dosing
• adrafinil (activator) — orexin neurons (prodrug → modafinil). modafinil prodrug; hepatic conversion; supplement-channel availability outside Rx
• caffeine (activator) — orexin disinhibition (via A1/A2A antagonism on orexin neurons). wake-promotion by removing adenosine inhibition of orexin firing; cross-link: caffeine_demethylation for clearance + adenosine receptors as direct target
• adenosine (inhibitor) — orexin firing (A1 on orexin neurons). endogenous sleep-pressure signal; accumulates across the waking day; CYP-independent (deaminated by ADA)
• ramelteon (activator) — MT1 + MT2 (melatonin agonist). Rozerem; non-controlled insomnia option; suvorexant alternative for sleep-onset
• tasimelteon (activator) — MT1 + MT2. Hetlioz; non-24-hour sleep-wake disorder (blind individuals)
• trazodone (inhibitor) — 5-HT2A + H1 + α1 (low-dose sleep aid). covered in atypical antidepressants — sleep use at low doses

References

• PMID 17299454